20
Views
0
CrossRef citations to date
0
Altmetric
Miscellaneous

New 2-amino-(5-cyanothiazol-2-yl) pyridines: KDR inhibitors with improved pharmacokinetic profile

Pages 1305-1312 | Published online: 02 Mar 2005

Bibliography

  • FOLKMAN J: Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. (2002) 29(6 Supp1.16):15–18.
  • •A good overview.
  • WALSH DA: Angiogenesis and arthritis. Rheumatology (1999) 38:103–112.
  • FERRARA N, ALITALO K: Clinical application of angiogenic growth factors and their inhibitors. Nat. Med. (1999) 5(12):1359–1364.
  • FERRARA N: Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin. Oncol (2002) 29(6 Supp1.16):10–14.
  • FERRARA N: Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int. (1999) 56:794–814.
  • CARMELIET P: Angiogenesis in health and disease. Nat. Med. (2003) 9(6):653–660.
  • •A recent review on angiogenesis.
  • BOYER SJ: Small molecule inhibitors of KDR (VEGFR-2) kinase: an overview of structure activity relationships. Corr. Top. Med. Chem. (2002)2:973–1000.
  • ••An extremely well documented medicinalchemistry review.
  • CONNELL RD: Patent focus on cancer chemotherapeutics V. Angiogenesis agents: September 2001 - August 2003. Expert Opin. Ther. Patents (2002) 12:1763–1782.
  • •A recently updated medicinal chemistry review.
  • TUCKER TJ, CIECKO PA, COLL KE et al.: Synthesis and biological evaluation of a series of novel and potent inhibitors of KDR kinase. 224th ACS National Meeting, Boston, USA (2002) MEDI220.
  • FRALEY ME, ANTANAVAGE J, ARRINGTON KL et al: Discovery, synthesis, SAR, and in vitrol in vivo characterization of a novel quinolinone class of VEGFR-2 kinase inhibitors. 224th ACS National Meeting, Boston, USA (2002) MEDI221.
  • MISRA R, XIAO H Y, KIM K et al: Discovery and development of acy1-2-aminothiazole cyclin-dependent kinase inhibitors with potent in vivo anti-tumor activity. 223th ACS National Meeting, Orlando, USA (2002) MEDI251.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.